SubsidieMeestersA first-in-class therapy for intestinal malabsorption in premature newborns
ELGN-GI is a pioneering drug aimed at accelerating gut maturation in preterm infants, reducing reliance on parenteral nutrition and lowering risks of infections and complications.
Projectdetails
Introduction
Around 10% of babies are born preterm, and premature birth is the 1st cause of newborn deaths. Preterm infants are born with an underdeveloped gastrointestinal (GI) tract, causing intestinal malabsorption.
Importance of Nutrition
At the first weeks of life, adequate nutrition is critical for brain and vital organ development. Therefore, infants are placed on central line nutrition until their GI is capable of absorbing sufficient nutrition.
Risks of Central Line Nutrition
However, central line nutrition is inadequate for critical growth and poses life-threatening risks. Thus, a fast transition to oral independence is the goal for improving outcomes.
ELGN-GI Drug Overview
ELGN-GI is the first drug for stimulating gut maturation for rapid transition to oral nutrition. It is safe and has demonstrated several benefits, including:
- Reducing dependency on Parenteral Nutrition by 4 days.
- Reducing hospitalization time by approximately 7 days in high-level NICU.
- Contributing to a 40% reduction in life-threatening infections and Necrotizing Enterocolitis.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.359.000 |
| Totale projectbegroting | € 3.370.000 |
Tijdlijn
| Startdatum | 1-11-2022 |
| Einddatum | 31-10-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ELGAN PHARMA LTD.penvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Bringing newborn care home: An integral mHealth solution for neonatal jaundice management.Picterus is creating a digital platform for at-home neonatal jaundice screening, empowering families to monitor conditions and streamline healthcare referrals, improving outcomes and resource efficiency. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Point of care diagnostic solution for definitive differentiation of true and false threatened preterm labour casesINNITIUS aims to optimize TPTL diagnosis with Fine Birth, a non-invasive AI-driven device that assesses cervical tissue consistency, seeking €2.5M for further development and regulatory approval. | EIC Accelerator | € 2.342.835 | 2023 | Details |
Temporary intraluminal bypass device designed to reduce the rate of diverting stoma and its related complication by at least 70%The CG-100 device aims to prevent anastomotic leakage in colorectal surgery by creating an internal bypass, improving patient quality of life and reducing healthcare costs significantly. | EIC Accelerator | € 2.269.312 | 2022 | Details |
Novel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD)The project aims to develop a novel treatment for celiac disease using a combination of gliadin protein, probiotic particles, and mouth patch technology, targeting market entry by 2029. | EIC Accelerator | € 2.499.993 | 2022 | Details |
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune systemi-Thymus aims to revolutionize treatment for babies born without a thymus by using gene therapy to create implantable thymus organoids, targeting clinical trials and market entry by 2028. | EIC Accelerator | € 2.495.510 | 2023 | Details |
Bringing newborn care home: An integral mHealth solution for neonatal jaundice management.
Picterus is creating a digital platform for at-home neonatal jaundice screening, empowering families to monitor conditions and streamline healthcare referrals, improving outcomes and resource efficiency.
Point of care diagnostic solution for definitive differentiation of true and false threatened preterm labour cases
INNITIUS aims to optimize TPTL diagnosis with Fine Birth, a non-invasive AI-driven device that assesses cervical tissue consistency, seeking €2.5M for further development and regulatory approval.
Temporary intraluminal bypass device designed to reduce the rate of diverting stoma and its related complication by at least 70%
The CG-100 device aims to prevent anastomotic leakage in colorectal surgery by creating an internal bypass, improving patient quality of life and reducing healthcare costs significantly.
Novel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD)
The project aims to develop a novel treatment for celiac disease using a combination of gliadin protein, probiotic particles, and mouth patch technology, targeting market entry by 2029.
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system
i-Thymus aims to revolutionize treatment for babies born without a thymus by using gene therapy to create implantable thymus organoids, targeting clinical trials and market entry by 2028.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the BrainPrometeus aims to personalize nutrition for premature neonates in NICUs through real-time adjustments of glucose and nutrients based on brain needs, reducing the risk of neurodevelopmental disabilities. | EIC Pathfinder | € 3.554.156 | 2023 | Details |
Innovatieve IV-set voor de neonatologieIn dit project ontwikkelen Innofuse en Promolding een innovatieve IV-set voor NICU's om de toediening van medicatie en voeding aan premature baby's te optimaliseren en doseringsproblemen te verminderen. | Mkb-innovati... | € 110.390 | 2019 | Details |
Artificial Placenta (ArtPlac) - Miniaturized Integrated Lung and Kidney Support for Critically Ill NewbornsThe ArtPlac project aims to revolutionize newborn care by developing a compact artificial placenta to reduce neonatal deaths and long-term complications through less invasive support. | EIC Pathfinder | € 4.229.608 | 2023 | Details |
Thuisbehandeling en monitoring van geelzucht bij pas- en vroeggeborenen: User flowHet project richt zich op het ontwikkelen van effectieve behandelingen voor geelzucht bij pasgeborenen, met speciale aandacht voor vroeggeborenen om neurologische schade te voorkomen. | Mkb-innovati... | € 20.000 | 2022 | Details |
Premature baby's draadloos monitoren met de Bambi BeltHet project ontwikkelt de Bambi Belt, een draadloos en huidvriendelijk monitoringsysteem voor premature baby’s, om stress en pijn te verminderen en de kwaliteit van zorg te verbeteren, wat ziekenhuisverblijven verkort en kosten verlaagt. | Mkb-innovati... | € 348.460 | 2017 | Details |
Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain
Prometeus aims to personalize nutrition for premature neonates in NICUs through real-time adjustments of glucose and nutrients based on brain needs, reducing the risk of neurodevelopmental disabilities.
Innovatieve IV-set voor de neonatologie
In dit project ontwikkelen Innofuse en Promolding een innovatieve IV-set voor NICU's om de toediening van medicatie en voeding aan premature baby's te optimaliseren en doseringsproblemen te verminderen.
Artificial Placenta (ArtPlac) - Miniaturized Integrated Lung and Kidney Support for Critically Ill Newborns
The ArtPlac project aims to revolutionize newborn care by developing a compact artificial placenta to reduce neonatal deaths and long-term complications through less invasive support.
Thuisbehandeling en monitoring van geelzucht bij pas- en vroeggeborenen: User flow
Het project richt zich op het ontwikkelen van effectieve behandelingen voor geelzucht bij pasgeborenen, met speciale aandacht voor vroeggeborenen om neurologische schade te voorkomen.
Premature baby's draadloos monitoren met de Bambi Belt
Het project ontwikkelt de Bambi Belt, een draadloos en huidvriendelijk monitoringsysteem voor premature baby’s, om stress en pijn te verminderen en de kwaliteit van zorg te verbeteren, wat ziekenhuisverblijven verkort en kosten verlaagt.